Ali McBride, PharmD
Chicago—Moving more patients into outpatient chemotherapy substantially reduced patient stays at the University of Arizona Cancer Center, in Tucson, and shifted about $1 million a year in costs for rituximab (Rituxan, Genentech) and clofarabine (Clolar, Sanofi) to the outpatient setting, according to an initiative presented during the 2016 Hematology/Oncology Pharmacy Association (HOPA) Oncology Pharmacy Practice Management Program.
With increasing pressures on